NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo

PURPOSE: Malignant pheochromocytoma (PCC) is a rare tumor with a very poor prognosis and no effective treatments. The aim of this study was to assess the efficacy of a novel second-generation synthetic heat-shock protein 90 (HSP90) inhibitor, NVP-AUY922, to treat malignant PCC in vitro and in vivo....

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Jianpo, Lin, Dengqiang, Xie, Xing, Xu, Yunze, Xu, Lieyu, Meng, Li, Zhu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403128/
https://www.ncbi.nlm.nih.gov/pubmed/28458565
http://dx.doi.org/10.2147/OTT.S130236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403128/
https://www.ncbi.nlm.nih.gov/pubmed/28458565
http://dx.doi.org/10.2147/OTT.S130236

Ejemplares similares